Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 4369431, 9 pages
http://dx.doi.org/10.1155/2016/4369431
Research Article

Integrated Analysis of DNA Methylation and mRNA Expression Profiles Data to Identify Key Genes in Lung Adenocarcinoma

1Department of Respiration, The First Hospital of Jilin University, Changchun 130021, China
2ICU Department, The First Hospital of Jilin University, Changchun 130021, China

Received 10 May 2016; Revised 21 June 2016; Accepted 21 June 2016

Academic Editor: Genichiro Ishii

Copyright © 2016 Xiang Jin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Subramanian and R. Govindan, “Lung cancer in never smokers: a review,” Journal of Clinical Oncology, vol. 25, no. 5, pp. 561–570, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. W. D. Travis, E. Brambilla, H. K. Muller-Hermelink, and C. C. Harris, Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart, World Health Organization, 2004.
  3. W. D. Travis, L. B. Travis, and S. S. Devesa, “Lung cancer,” Cancer, vol. 75, supplement 1, pp. 191–202, 1995. View at Publisher · View at Google Scholar
  4. R. S. Mitchell, V. Kumar, A. K. Abbas, and N. Fausto, “Box on morphology of adenocarcinoma,” in Robbins Basic Pathology, chapter 13, Elsevier, 2006. View at Google Scholar
  5. International Agency for Research on Cancer, World Cancer Report 2014, WHO, Geneva, Switzerland, 2014.
  6. D. X. Nguyen, A. C. Chiang, X. H.-F. Zhang et al., “WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis,” Cell, vol. 138, no. 1, pp. 51–62, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. S.-H. Chiou, M.-L. Wang, Y.-T. Chou et al., “Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell–like properties and epithelial–mesenchymal transdifferentiation,” Cancer Research, vol. 70, no. 24, pp. 10433–10444, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Tano, R. Mizuno, T. Okada et al., “MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes,” FEBS Letters, vol. 584, no. 22, pp. 4575–4580, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Ren, F. Wang, J. Shen et al., “Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer,” European Journal of Cancer, vol. 49, no. 13, pp. 2949–2959, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Naoki, T.-H. Chen, W. G. Richards, D. J. Sugarbaker, and M. Meyerson, “Missense mutations of the BRAF gene in human lung adenocarcinoma,” Cancer Research, vol. 62, no. 23, pp. 7001–7003, 2002. View at Google Scholar · View at Scopus
  11. R. De Oliveira Duarte Achcar, M. N. Nikiforova, and S. A. Yousem, “Micropapillary Lung adenocarcinoma EGFR, K-ras, and BRAF mutational profile,” American Journal of Clinical Pathology, vol. 131, no. 5, pp. 694–700, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. C.-C. Ho, P.-H. Huang, H.-Y. Huang, Y.-H. Chen, P.-C. Yang, and S.-M. Hsu, “Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation,” The American Journal of Pathology, vol. 161, no. 5, pp. 1647–1656, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Barrett, D. B. Troup, S. E. Wilhite et al., “NCBI GEO: archive for functional genomics data sets-10 years on,” Nucleic Acids Research, vol. 39, supplement 1, pp. D1005–D1010, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Du, W. A. Kibbe, and S. M. Lin, “lumi: a pipeline for processing Illumina microarray,” Bioinformatics, vol. 24, no. 13, pp. 1547–1548, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Smyth, “Limma: linear models for microarray data,” in Bioinformatics and Computational Biology Solutions using R and Bioconductor, R. Gentleman, V. Carey, S. Dudoit, R. Irizarry, and W. Huber, Eds., pp. 397–420, Springer, New York, NY, USA, 2005. View at Google Scholar
  16. Y. Benjamini, “Discovering the false discovery rate,” Journal of the Royal Statistical Society: Series B—Statistical Methodology, vol. 72, no. 4, pp. 405–416, 2010. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  17. S. Tweedie, M. Ashburner, K. Falls et al., “FlyBase: enhancing drosophila gene ontology annotations,” Nucleic Acids Research, vol. 37, supplement 1, pp. D555–D559, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Kanehisa and S. Goto, “KEGG: kyoto encyclopedia of genes and genomes,” Nucleic Acids Research, vol. 28, no. 1, pp. 27–30, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. L. M. Schriml, C. Arze, S. Nadendla et al., “Disease ontology: a backbone for disease semantic integration,” Nucleic Acids Research, vol. 40, no. 1, pp. D940–D946, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. Y.-A. Chen, L. P. Tripathi, and K. Mizuguchi, “TargetMine, an integrated data warehouse for candidate gene prioritisation and target discovery,” PLoS ONE, vol. 6, no. 3, Article ID e17844, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Van Belle, L. D. Fisher, P. J. Heagerty, and T. Lumley, Biostatistics: A Methodology for the Health Sciences, John Wiley & Sons, New York, NY, USA, 2004.
  22. C. Von Mering, L. J. Jensen, M. Kuhn et al., “STRING 7—recent developments in the integration and prediction of protein interactions,” Nucleic Acids Research, vol. 35, supplement 1, pp. D358–D362, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Saito, M. E. Smoot, K. Ono et al., “A travel guide to Cytoscape plugins,” Nature Methods, vol. 9, no. 11, pp. 1069–1076, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Csardi and T. Nepusz, “The igraph software package for complex network research,” International Journal of Complex Systems, vol. 1695, no. 5, pp. 1–9, 2006. View at Google Scholar
  25. G. D. Bader and C. W. V. Hogue, “An automated method for finding molecular complexes in large protein interaction networks,” BMC Bioinformatics, vol. 4, no. 1, article 2, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Maere, K. Heymans, and M. Kuiper, “BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks,” Bioinformatics, vol. 21, no. 16, pp. 3448–3449, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Gentleman, V. Carey, W. Huber, and F. Hahne, “Genefilter: methods for filtering genes from microarray experiments,” R Package Version, vol. 1, 2011.
  28. R. T. Barfield, V. Kilaru, A. K. Smith, and K. N. Conneely, “CpGassoc: an R function for analysis of DNA methylation microarray data,” Bioinformatics, vol. 28, no. 9, pp. 1280–1281, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. C.-L. Huang, D. Liu, J. Nakano et al., “Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor—an expression in non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 23, no. 34, pp. 8765–8773, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. D. J. Stewart, “Wnt signaling pathway in non-small cell lung cancer,” Journal of the National Cancer Institute, vol. 106, no. 1, Article ID djt356, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. R. A. Winn, L. Marek, S.-Y. Han et al., “Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through Frizzled-9-mediated growth inhibition and promotion of cell differentiation,” The Journal of Biological Chemistry, vol. 280, no. 20, pp. 19625–19634, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Kato, Y. Daigo, M. Aragaki, K. Ishikawa, M. Sato, and M. Kaji, “Overexpression of CDC20 predicts poor prognosis in primary non-small cell lung cancer patients,” Journal of Surgical Oncology, vol. 106, no. 4, pp. 423–430, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. D. Stav, I. Bar, and J. Sandbank, “Usefulness of CDK5RAP3, CCNB2, and RAGE genes for the diagnosis of lung adenocarcinoma,” The International Journal of Biological Markers, vol. 22, no. 2, pp. 108–113, 2007. View at Google Scholar · View at Scopus
  34. S. Takashima, H. Saito, N. Takahashi et al., “Strong expression of cyclin B2 mRNA correlates with a poor prognosis in patients with non-small cell lung cancer,” Tumor Biology, vol. 35, no. 5, pp. 4257–4265, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. X. Qian, X. Song, Y. He et al., “CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients,” Biomedicine & Pharmacotherapy, vol. 74, pp. 222–227, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. S. L. Smith, N. L. Bowers, D. C. Betticher et al., “Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability,” British Journal of Cancer, vol. 93, no. 6, pp. 719–729, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Vischioni, J. J. Oudejans, W. Vos, J. A. Rodriguez, and G. Giaccone, “Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients,” Molecular Cancer Therapeutics, vol. 5, no. 11, pp. 2905–2913, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Hayama, Y. Daigo, T. Yamabuki et al., “Phosphorylation and activation of cell division cycle associated 8 by aurora kinase B plays a significant role in human lung carcinogenesis,” Cancer Research, vol. 67, no. 9, pp. 4113–4122, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Kato, Y. Daigo, M. Aragaki et al., “Overexpression of MAD2 predicts clinical outcome in primary lung cancer patients,” Lung Cancer, vol. 74, no. 1, pp. 124–131, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Dasgupta, J. S. Jang, C. Shao et al., “SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling,” Journal of Molecular Medicine, vol. 91, no. 3, pp. 381–393, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. M. F. Bari, H. Brown, A. G. Nicholson et al., “BAI3, CDX2 and VIL1: a panel of three antibodies to distinguish small cell from large cell neuroendocrine lung carcinomas,” Histopathology, vol. 64, no. 4, pp. 547–556, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. K. O. Toyooka, S. Toyooka, A. K. Virmani et al., “Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas,” Cancer Research, vol. 61, no. 11, pp. 4556–4560, 2001. View at Google Scholar · View at Scopus
  43. P. Ulivi, W. Zoli, D. Calistri et al., “p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients,” Journal of Cellular Physiology, vol. 206, no. 3, pp. 611–615, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Seuk Kim, J. Han, Y. M. Shim, J. Park, and D.-H. Kim, “Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma,” Cancer, vol. 104, no. 9, pp. 1825–1833, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Hao, Y. Yang, Y. Liu et al., “JAM-C promotes lymphangiogenesis and nodal metastasis in non-small cell lung cancer,” Tumor Biology, vol. 35, no. 6, pp. 5675–5687, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. M. G. Joseph, D. Banerjee, W. Kocha, R. Feld, L. W. Stitt, and M. G. Cherian, “Metallothionein expression in patients with small cell carcinoma of the lung: correlation with other molecular markers and clinical outcome,” Cancer, vol. 92, no. 4, pp. 836–842, 2001. View at Google Scholar · View at Scopus
  47. S. Theocharis, C. Karkantaris, T. Philipides et al., “Expression of metallothionein in lung carcinoma: correlation with histological type and grade,” Histopathology, vol. 40, no. 2, pp. 143–151, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. W.-B. Liu, X. Jiang, F. Han et al., “LHX6 acts as a novel potential tumour suppressor with epigenetic inactivation in lung cancer,” Cell Death and Disease, vol. 4, no. 10, article e882, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. I. I. de Caceres, M. Cortes-Sempere, C. Moratilla et al., “IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer,” Oncogene, vol. 29, no. 11, pp. 1681–1690, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. S. J. London, J.-M. Yuan, G. S. Travlos et al., “Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China,” Journal of the National Cancer Institute, vol. 94, no. 10, pp. 749–754, 2002. View at Publisher · View at Google Scholar · View at Scopus